A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

NCT02266927 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Asthma

Interventions

DRUG: Flovent HFA
DRUG: OPTINOSE™ FLUTICASONE

Sponsor

Optinose US Inc.